A Dose-Escalation Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of IPI-549
This dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IPI-549 monotherapy and IPI-549 in combination with nivolumab in subjects with advanced solid tumors.
A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination with Nivolumab in Subjects with Advanced Solid Tumors
- ClinicalTrials.gov Identifier: NCT02637531
- Protocol Number: 16-008
- Principal Investigator: James Mier
- Principal Investigator: Central PIO
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required